POLA1 · Western blot design guide

POLA1 Western Blot Planning Guide

Plan a POLA1 Western blot around the catalog-observed 165.9 kDa band, image-backed A04421-1 evidence, HPA controls, and verified protocol records.

Evidence assembled July 2026 · For research use; verify linked source records and product datasheet before use
Western blot protocol sheet for POLA1 (POLA1): expected band 165.9 kDa, antibody A04421-1, and guide-derived SDS-PAGE protocol steps
POLA1 Western blot protocol sheet — expected band 165.9 kDa, antibody A04421-1, controls and PMC citations. Open the full POLA1 WB guide →

POLA1 Western Blot Experimental Design Guide

Expected bands, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.

Must know before running
Expected band 165.9 kDa
Observed band Not reported — verify product WB image
Gel 8-10%
Positive control ⓘ Cervix
Negative control ⓘ Skeletal muscle
Important caveats
Reasons your observed band may differ from the expected size.
ⓘ Calculated mass 165.9 kDa
ⓘ Localization Nucleus / Cytoplasm, cytosol
ⓘ Processing / PTM Record-dependent
ⓘ Reactivity Human
Section 1

Real Curated POLA1 Western Blot Protocols

Start with the molecular-weight rule, then compare verified publication-derived conditions.

Recommended Western blot protocol parameters
Sample / lysateAppendix
Gel %8-10%
Load20-30 µg total protein per lane
TransferWet/tank, extended transfer
Membrane0.45 µm PVDF
Blocking5% non-fat milk or 5% BSA in TBST
PrimaryA04421-1 at datasheet starting dilution
Primary incubationOvernight at 4 °C with gentle agitation
SecondarySpecies-matched HRP conjugate at validated dilution
Wash3 × 5 min in TBST
DetectionChemiluminescent substrate
ExposureBracket exposures to avoid saturation
Section 2

What Is the Expected POLA1 Western Blot Band Size?

Use the product-observed 165.9 kDa band as the primary planning value and retain the UniProt calculated mass as context.

What am I looking at on my blot?
165.9 kDaMatches the authoritative product WB observation.
165.9 kDa calculatedUse as UniProt context, not as a replacement observed band.
Unexpected additional signalDo not assign identity without orthogonal positive/negative controls.
💡Expected POLA1 appearancePlan around 165.9 kDa and keep the calculated mass as supporting context.
How each factor affects band size
Catalog-observed band165.9 kDa; use this as the primary experimental expectation.
Calculated mass165.9 kDa from UniProt P09884; retain as context.
Gel selection8-10%; shared with the recommended protocol and poster.
Specificity checkCompare the lead HPA positive and negative controls with A04421-1.
Why is my band missing or off?
SituationLikely causeNext action
165.9 kDaMatches the authoritative product WB observation.Confirm with orthogonal controls and the linked product record.
Additional bandMay reflect processing, modification, or non-specific signal.Run a dilution series and compare positive/negative controls.
Weak signalTarget abundance or transfer may be limiting.Verify transfer, increase positive-control abundance, and bracket exposure.

Sample controls for POLA1 Western blot

🧪Use Cervix as the first positive-control candidate and Skeletal muscle as the HPA Not detected negative candidate.
Positive control: Cervix (High)
Negative control: Skeletal muscle (Not detected)
HPA protein score determines control status; other expression data is supporting context only.

HPA tissue expression evidence for POLA1

Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.

Positive expression · recommended positive controls

TissueCell typeLevelEvidenceSource
Cervix Reported tissue cells High Protein (HPA) HPA →
Colon Reported tissue cells High Protein (HPA) HPA →
Appendix Reported tissue cells High Protein (HPA) HPA →
Bone marrow Reported tissue cells High Protein (HPA) HPA →

Undetected expression · recommended negative controls

TissueCell typeLevelEvidenceSource
Skeletal muscle Reported tissue cells Not detected Protein (HPA) HPA →
Soft tissue Reported tissue cells Not detected Protein (HPA) HPA →
Section 3

Advanced POLA1 Western Blot Tips

Deeper troubleshooting and optimisation questions for POLA1, answered from its protein features.

Which band should guide the blot?
Use 165.9 kDa, the observation attached to the authoritative A04421-1 WB record.
How should calculated mass be interpreted?
Treat the UniProt calculated mass as context; it does not replace the catalog-observed 165.9 kDa expectation.
Which positive control should I start with?
Start with Cervix, the lead HPA protein-expression candidate.
Which negative control is defensible?
Use Skeletal muscle as an orthogonal HPA Not detected candidate.
Which gel should I use?
Use 8-10% consistently across the quick facts, protocol table, and poster.
What transfer method to use for POLA1 Western blot?
Use the transfer method in the recommended protocol and verify transfer before blocking.
How should A04421-1 be started?
Start at the linked datasheet condition and run a three-point primary-antibody dilution test.
Which publication-derived protocols can I compare?
No verified publication protocol was supplied; use only the deterministic recommended protocol.
Boster reagents

POLA1 Western Blot Reagents

Human-reactive POLA1 Western blot reagents with authoritative product imagery.

Real WB data Western blot validation image for POLA1 using A04421-1; observed band 165.9 kDa
Anti-POLA1 Antibody Picoband®
Cat # A04421-1

Only image-backed, WB-validated Human/Mouse/Rat recommendations from the prepared catalog evidence are shown.

Source: prepared picoband-wb product evidence; each card retains its own SKU, URL, observed band, and authoritative WB image.

References

  1. UniProt P09884
  2. Human Protein Atlas — POLA1
  3. A04421-1 product record
  4. PMC4836962 — DNA polymerase-α regulates the activation of type I interferons through cytosolic RNA:DNA synthesis (Nature immunology, 2016)
  5. PMC11369380 — Synthetic lethality between ATR and POLA1 reveals a potential new target for individualized cancer therapy (Neoplasia (New York, N.Y.), 2024)